11/17/2010 8:47:39 AM
FARMINGDALE, N.Y., Nov. 16, 2010 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced its achievement of contract vendor status with Select Medical Corporation, based in Mechanicsburg, PA, for its SonicOne® Ultrasonic Wound Cleansing and Debridement System. As a result of this status, specialty hospitals, without further approval, can easily arrange for system valuations and issue purchase orders for disposable products, accessories and system rentals.
Select Medical Corporation is an operating unit of Select Medical Holdings (NYSE: SEM), a leading operator of specialty hospitals, including 111 Long Term Acute Care ("LTACH") facilities and 6 Acute Rehabilitation facilities located in 28 states. These facilities operate as Select Specialty Hospitals, Regency Specialty Hospitals and Great Lakes Specialty Hospitals. Select also operates approximately 950 Out Patient Rehabilitation Clinics in 36 states and provides contract Medical Rehabilitation Services to over 400 skilled nursing, assisted living, senior care, school and worksite locations. Misonix's contract vendor status is focused on the LTACH facilities, which provide care and rehabilitation for trauma victims and other serious and complex medical conditions.
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix is excited by the potential for expanded clinical use of our ultrasonic wound management technology via an association with a high caliber organization such as Select Medical," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The clinical benefits for patient and physician over traditional means of wound cleansing and debridement are evident. This is another example of our commitment to state-of-the-art medical devices for use by the worldwide medical community working in cooperation with highly regarded healthcare providers."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.